target directory

adenosine adenosine mono phosphate amp clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT00179010
Source recordAI-normalized

Use of AMP to Improve Tissue Delivery of Adenosine

Adenosine and AMP are substances normally present in the body. Adenosine is also given for the treatment of some heart rhythm problems and may be used to reduce heart damage during heart attacks. The problem in using adenosine is that it is taken up by cells and, therefore, very little of the adenosine we give by vein or in the artery actually reaches the tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is inactive by itself, but is converted to adenosine in tissue. We hope that by giving AMP we will increase levels of adenosine in tissue. To see if this is true, we will give either adenosine or AMP into the forearm artery while we measure how much adenosine reaches the forearm tissue.

AI analysis

Indication: Ischemia

Modality: small molecule

Target: Adenosine, Adenosine Mono Phosphate (AMP)

Sponsor: Vanderbilt University Medical Center

Source URL: ClinicalTrials.gov

Source updated: May 07, 2019

Ingested: Jun 08, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Adenosine, Adenosine Mono Phosphate (AMP)

View original source fields

Condition raw: Ischemia

Condition normalized: Ischemia

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Adenosine, Adenosine Mono Phosphate (AMP)

Target normalized: Adenosine, Adenosine Mono Phosphate (AMP)

Open report